Avalo Therapeutics Inc. Revenue 2015–2025
Avalo Therapeutics Inc. annual/quarterly revenue history and growth rate from 2015 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Avalo Therapeutics Inc. revenue for the quarter ending September 30, 2025 was 0, a 100.00% decrease year-over-year.
- Avalo Therapeutics Inc. revenue for the twelve months ending September 30, 2025 was 249000, a 98.47% decrease year-over-year.
- Avalo Therapeutics Inc. annual revenue for 2025 was 59000, a 86.62% decrease from 2024.
- Avalo Therapeutics Inc. annual revenue for 2024 was 441000, a 77.08% decrease from 2023.
- Avalo Therapeutics Inc. annual revenue for 2023 was 1.9 M, a 89.34% decrease from 2022.
- Avalo Therapeutics Inc. annual revenue for 2022 was 18.1 M.
Avalo Therapeutics Inc. (AVTX) — Frequently Asked Questions
Avalo Therapeutics Inc. (AVTX) is a publicly traded US company. It has a market capitalization of $176M. In fiscal 2025 it reported revenue of $59,000 and net income of -$78M. Explore AVTX's stock price, financial statements, earnings history, margins and key ratios below.
What is Avalo Therapeutics Inc.'s market cap?
Avalo Therapeutics Inc. (AVTX) has a market capitalization of $176M.
What is the AVTX stock price?
AVTX trades at $13.10 (+1.55% on the day).
How much revenue does Avalo Therapeutics Inc. make?
Avalo Therapeutics Inc. reported revenue of $59,000 in fiscal 2025.
Is AVTX profitable?
In fiscal 2025, Avalo Therapeutics Inc. reported net income of -$78M.